Dear EURETINA Members, A very warm welcome to the April 14th, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »April 14th, 2025 “EURETINA-Brief”© Issue No. 314
Researchers at the Department of Genetics, and the Department of Ophthalmology, Harvard Medical School, Boston, have reported a novel gene-agnostic strategy treating retinitis pigmentosa (RP),… Read More »Novel research on a gene-agnostic strategy to treat RP aims to improve cone cell survival and extend vision.
Clinical researchers at the Sorbonne Université, INSERM, Institut de la Vision, Paris, have reported multiple pathogenic variants in the RP1L1 gene, associated with autosomal dominant,… Read More »Clinical analysis of phenotypic and genotypic characteristics on retinitis pigmentosa-1-like-1 (RP1L1) show associated retinopathy.
Atsena Therapeutics, based in Durham, North Carolina, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ATSN-201, for… Read More »Atsena Therapeutics has announced the grant of U.S. FDA Fast Track Designation for ATSN-201 gene therapy for the treatment of X-linked retinoschisis.
Dear EURETINA Members, A very warm welcome to the March 31st, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »March 31st, 2025 “EURETINA-Brief”© Issue No. 313
Researchers at the Institute of Molecular and Clinical Ophthalmology Basel (IOB), Switzerland, and the Centre for Medical Genetics, Ghent University, Belgium, have reported results of… Read More »A specific form of macular degeneration (MD) has uncovered three novel genetic variants encoding an adaptor protein (AP-5) complex, essential for macular function.
EMA (European Medicines Authority) officials have launched a new clinical trial map aimed to provide access to the public for “patients and healthcare professionals with… Read More »EMA launches a new clinical trial map aimed at increasing access to clinical research studies in the European Union (EU).
Opthea Limited (ASX/NASDAQ: OPT), based in Melbourne, Australia and Princeton, New Jersey, have announced summary results from its global Phase 3 clinical trial “COAST” (Combination… Read More »Opthea Ltd (ASX/NASDAQ: OPT) have announced summary Phase 3 results for OPT-302 (sozinibercept) for wet AMD, following suspending shares at the Australian and NASDAQ exchanges.
Dear EURETINA Members, A very warm welcome to the March 17th, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »March 17th, 2025 “EURETINA-Brief”© Issue No. 312
Researchers at the Department of Optometry and Vision Sciences, and the Ophthalmology Department of Surgery, based in the University of Melbourne, Australia, has reported results… Read More »Variability disease in female carriers of RPGR variants show clinical and genetic parameters in XLRP.
